References
- Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med.331, 496–501 (1994).
- Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N. Engl. J. Med.331, 489–495 (1994).
- Grube E, Silber S, Hauptmann KE et al. Taxus I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation107, 38–42 (2003).
- Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med.346, 1773–1780 (2002).
- Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med.349, 1315–1323 (2003).
- Stone GW, Ellis SG, Cox DA et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting Taxus stent: the TAXUS-IV trial. Circulation109, 1942–1947 (2004).
- Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med.350, 221–231 (2004).
- Marroquin OC, Selzer F, Mulukutla SR et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N. Engl. J. Med.358, 342–352 (2008).
- Win HK, Caldera AE, Maresh K et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA297, 2001–2009 (2007).
- McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet364, 1519–1521 (2004).
- Wenaweser P, Daemen J, Zwahlen M et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J. Am. Coll. Cardiol.52, 1134–1140 (2008).
- Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet369, 667–678 (2007).
- Ozaki Y, Okumura M, Ismail TF et al. The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study. Eur. Heart J.31, 1470–1476 (2010).
- Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation120, 391–399 (2009).
- Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo)28, 721–726 (1975).
- Gallo R, Padurean A, Jayaraman T et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation99, 2164–2170 (1999).
- Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res.76, 412–417 (1995).
- Roque M, Cordon-Cardo C, Fuster V, Reis ED, Drobnjak M, Badimon JJ. Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model. Atherosclerosis153, 315–322 (2000).
- Schofer J, Schluter M, Gershlick AH et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet362, 1093–1099 (2003).
- Schampaert E, Cohen EA, Schluter M et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J. Am. Coll. Cardiol.43, 1110–1115 (2004).
- Caixeta A, Leon MB, Lansky AJ et al. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J. Am. Coll. Cardiol.54, 894–902 (2009).
- Ikari Y, Kotani J, Kozuma K, Kyo E, Nakamura M, Yokoi H. Assessment of sirolimus-eluting coronary stent implantation with aspirin plus low dose ticlopidine administration: one year results from CYPHER Stent Japan Post-Marketing Surveillance Registry (J-PMS). Circ. J.73, 1038–1044 (2009).
- Kelbaek H, Klovgaard L, Helqvist S et al. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. J. Am. Coll. Cardiol.51, 2011–2016 (2008).
- Urban P, Gershlick AH, Guagliumi G et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation113, 1434–1441 (2006).
- Zahn R, Hamm CW, Schneider S et al. Coronary stenting with the sirolimus-eluting stent in clinical practice: final results from the prospective multicenter German Cypher Stent Registry. J. Interv. Cardiol.23(1), 18–25 (2010).
- Muldowney JA, III, Stringham JR, Levy SE et al. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler. Thromb. Vasc. Biol.27, 400–406 (2007).
- Steffel J, Latini RA, Akhmedov A et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation112, 2002–2011 (2005).
- Stahli BE, Camici GG, Steffel J et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ. Res.99, 149–155 (2006).
- Colombo A, Drzewiecki J, Banning A et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation108, 788–794 (2003).
- Stone GW, Ellis SG, Cannon L et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA294, 1215–1223 (2005).
- Tanabe K, Serruys PW, Grube E et al. TAXUS III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation107, 559–564 (2003).
- Ellis SG, Cannon LA, Mann T et al. Final 5-year outcomes from the TAXUS V de novo trial: long-term safety and effectiveness of the paclitaxel-eluting Taxus stent in complex lesions. Am. J. Cardiol.104, 135D (2009).
- Ellis SG, Stone GW, Cox DA et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc. Interv.2, 1248–1259 (2009).
- Turco MA, Ormiston JA, Popma JJ et al. Polymer-based, paclitaxel-eluting Taxus Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial. J. Am. Coll. Cardiol.49, 1676–1683 (2007).
- Turco MA, Ormiston JA, Popma JJ et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut Taxus Liberté stent: 1-year results from the Taxus ATLAS program. JACC Cardiovasc. Interv.1, 699–709 (2008).
- Kereiakes DJ. Taxus PERSEUS workhorse. Presented at: ACC/I2 Scientific Sessions 2010. Atlanta, GA, USA, 15 March 2010 (Abstract).
- Hayward JA, Chapman D. Biomembrane surfaces as models for polymer design: the potential for haemocompatibility. Biomaterials5, 135–142 (1984).
- Leon MB, Mauri L, Popma JJ et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the Taxus paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J. Am. Coll. Cardiol.55, 543–554 (2010).
- Kandzari DE, Leon MB, Popma JJ et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J. Am. Coll. Cardiol.48, 2440–2447 (2006).
- Camenzind E, Wijns W, Mauri L et al. Rationale and design of the Patient Related Outcomes with Endeavor versus Cypher Stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. Am. Heart J.158, 902–909 (2009).
- Grube E, Buellesfeld L. BioMatrix biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev. Med. Devices3, 731–741 (2006).
- Costa RA, Lansky AJ, Abizaid A et al. Angiographic results of the first human experience with the biolimus A9 drug-eluting stent for de novo coronary lesions. Am. J. Cardiol.98, 443–446 (2006).
- Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet372, 1163–1173 (2008).
- Klauss V. LEADERS: a prospective, randomised, non-inferiority trial comparing biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer: 2-year clinical follow-up. Presented at: Transcatheter Cardiovascular Therapeutics 2009. San Francisco, CA, USA, 23 September 2010 (Abstract).
- Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation64, 36–42 (1997).
- Vitko S, Margreiter R, Weimar W et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am. J. Transplant.5, 2521–2530 (2005).
- Snell GI, Valentine VG, Vitulo P et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am. J. Transplant.6, 169–177 (2006).
- Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med.349, 847–858 (2003).
- Perkins EL, Boeke-Purkis BS, Wang Q, Stringer SK, Coleman LA. Xience V everolimus-eluting coronary stent system: a preclinical assessment. J. Interv. Cardiol.22, S28–S40 (2009).
- Ding N, Pacetti S, Tang F, Gada M, Roorda W. Xience V stent design and rational. J. Interv. Cardiol.22, S18–S27 (2009).
- Pache J, Kastrati A, Mehilli J et al. Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO-2) trial. J. Am. Coll. Cardiol.41, 1283–1288 (2003).
- Kastrati A, Mehilli J, Dirschinger J et al. Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) trial. Circulation103, 2816–2821 (2001).
- Rittersma SZ, de Winter RJ, Koch KT et al. Impact of strut thickness on late luminal loss after coronary artery stent placement. Am. J. Cardiol.93, 477–480 (2004).
- Finn AV, Joner M, Nakazawa G et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation115, 2435–2441 (2007).
- Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol.48, 193–202 (2006).
- Joner M, Nakazawa G, Finn AV et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol.52, 333–342 (2008).
- Grube E, Sonoda S, Ikeno F et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation109, 2168–2171 (2004).
- Tsuchiya Y, Lansky AJ, Costa RA et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am. J. Cardiol.98, 464–469 (2006).
- Serruys PW, Ong AT, Piek JJ et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT FIRST trial. EuroIntervention1, 58–65 (2005).
- Tsuchida K, Piek JJ, Neumann FJ et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (the SPIRIT FIRST Trial). EuroIntervention1, 266–272 (2005).
- Wiemer M, Serruys P, Miquel-Hebert K et al. Five-year long-term clinical follow-up of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. Catheter. Cardiovasc. Interv.75(7), 997–1003 (2010).
- Serruys PW, Ruygrok P, Neuzner J et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention2, 286–294 (2006).
- Claessen BE, Beijk MA, Legrand V et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the Xience V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. Circ. Cardiovasc. Interv.2, 339–347 (2009).
- Garg S, Serruys P, Onuma Y et al. 3-year clinical follow-up of the Xience V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). JACC Cardiovasc. Interv.2, 1190–1198 (2009).
- Stone GW, Midei M, Newman W et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA299, 1903–1913 (2008).
- Stone G. Three-year outcome of the SPIRIT III trial. Presented at: Transcatheter Cardiovascular Therapeutics (TCT). San Francisco, CA, USA, 21 September 2009.
- Gordon PC, Applegate RJ, Hermiller JB et al. Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry. Catheter. Cardiovasc. Interv.75, 179–186 (2010).
- Stone GW, Rizvi A, Newman W et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N. Engl. J. Med.362, 1663–1674 (2010).
- Cutlip DE, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation115, 2344–2351 (2007).
- Grube E. SPIRIT V diabetic randomised controlled trial: 1 year results. Presented at: EUROPCR 2010. Paris, France, 25 May 2010.
- Kedhi E, Joesoef KS, McFadden E et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet375, 201–209 (2010).
- Serruys PW. Twelve months primary endpoint results of the RESOLUTE all-comers trial: a randomised comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention. Presented at: EUROPCR 2010. Paris, France, 25 May 2010.
- Byrne RA, Kastrati A, Kufner S et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) trial. Eur. Heart J.30, 2441–2449 (2009).
- Onuma Y, Kukreja N, Piazza N et al. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. J. Am. Coll. Cardiol.54, 269–276 (2009).
- Latib A, Ferri L, Ielasi A et al. Clinical outcomes after unrestricted implantation of everolimus-eluting stents. JACC Cardiovasc. Interv.2, 1219–1226 (2009).
- Grube E. SPIRIT V registry: one-year follow-up. Presented at: EUROPCR 2009. Barcelona, Spain, 21 May 2009.
- Serruys PW, Morice MC, Kappetein AP et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med.360, 961–972 (2009).
- Claessen BE, Stone GW, Smits PC et al. Would SYNTAX have been a positive trial if Xience V was used in stead of TAXUS? A meta-analysis of a first-generation vs. a second generation drug eluting stent system. Neth. Heart. J.18, 451–453 (2010).
- Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet371, 899–907 (2008).
- Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet373, 897–910 (2009).
Website
- Abbott Vascular press release: Xience Prime stent receives CE approval http://abbott.com/global/url/pressRelease/en_US/60 5:5/Press_Release_0742.htm (Accessed 1 June 2010)